A Phase I, Open-Label Study to Assess the Effect of Dosing AZD6244 HydSulfate [AZD-6244] in the Presence and Absence of Food in Patients With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2014
At a glance
- Drugs Selumetinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 01 Dec 2011 Results published in Cancer Chemotherapy and Pharmacology.
- 23 Nov 2010 New source identified and integrated (United Kingdom Clinical Research Network).
- 12 May 2010 Actual patient number (30) added as reported by ClinicalTrials.gov.